T-cell Non-hodgkin Lymphoma
📧 Sign up to get email alerts when something new happens for T-cell Non-hodgkin Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances [Phase 1, Phase 2]
A Phase I/II clinical trial evaluating CAR.70, engineered IL-15-transduced cord blood-derived natural killer (NK) cells, in combination with…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating pralatrexate with bendamustine and total-body irradiation followed by donor stem cell transplant for r…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: CD45BE-HSPC + CART-45 Cells [Phase 1]
Phase 1 study evaluating CD45BE-HSPC with CART-45 cells is not yet recruiting and targets B-cell non-Hodgkin lymphoma and Richter transforma…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells [Phase 1]
A Phase 1 clinical trial update on an allogeneic CD7-targeted CAR-T cell therapy for high-risk T-cell malignancies (T-cell acute lymphoblast…
-
CLINICAL_TRIALS research · 2025-11-10Clinical Trial Update: CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL) [Phase 1]
A Phase 1 trial update indicates recruitment for Senza5 CART5, CD5-deleted CAR T cells, targeting T-cell non-Hodgkin lymphoma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-10-23Clinical Trial Update: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells [Phase 1]
A Phase 1 clinical trial evaluates CD7-targeted CAR-T cells derived from autologous T cells for high-risk T-cell malignancies and is current…
-
CLINICAL_TRIALS research · 2025-09-04Clinical Trial Update: Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen [Phase 1]
Phase 1 trial evaluating autologous CD5-targeted CAR T cells for T-cell malignancies expressing CD5, currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-13Clinical Trial Update: CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas [Phase 1, Phase 2]
A Phase 1/Phase 2 clinical trial evaluating CD7-directed CAR T-cell therapy for relapsed/refractory T-cell lymphomas (including PTCL and CTC…
-
CLINICAL_TRIALS research · 2025-04-29Clinical Trial Update: Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 dose-escalation and dose-expansion study of anti-CD7 allogeneic CAR T-cells (WU-CART-007) in …
-
CLINICAL_TRIALS research · 2016-12-08Clinical Trial Update: Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating chidamide with CHOEP chemotherapy and upfront autologous stem cell transplant in untreated peripheral …
-
CLINICAL_TRIALS research · 2013-09-20Clinical Trial Update: Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]
This clinical trial investigates the use of alemtuzumab in combination chemotherapy for newly diagnosed stage II, stage III, or stage IV T-c…
-
CLINICAL_TRIALS research · 2012-10-24Clinical Trial Update: Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma. [Phase 1, Phase 2]
Terminated Phase 1/2 pharmacokinetic study of forodesine in children with relapsed or refractory T-cell or B-cell precursor acute lymphoblas…